Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Piramal Critical Care Limited, Suite 4, Ground Floor, Heathrow Boulevard East Wing, 280 Bath Road, West Drayton, UB7 0DQ, United Kingdom
Yargesa 100 mg hard capsules.
| Pharmaceutical Form |
|---|
|
Hard capsule. The hard capsule consists of an opaque white cap and body with “708” printed in black on the body. Capsule Size: 4 (14.3 mm x 5.3 mm). |
Each hard capsule contains 100 mg miglustat.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Miglustat |
Miglustat is an inhibitor of glucosylceramide synthase, the enzyme responsible for the first step in the synthesis of most glycolipids, and a pharmacokinetic enzyme stabiliser of cipaglucosidase alfa. Miglustat is indicated for the treatment of adult patients with mild to moderate type 1 Gaucher disease and for the treatment of progressive neurological manifestations in patients with Niemann-Pick type C disease. Also, miglustat must be used in combination with cipaglucosidase alfa for long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency). |
| List of Excipients |
|---|
|
Capsule content: Sodium starch glycolate (Type A) Capsule shell: Gelatin Printing ink: Shellac glaze |
PVC and polychlorotrifluoroethylene (PCTFE) blister sealed with aluminium foil containing 21 capsules.
Pack size: 84 × 1 capsules.
Piramal Critical Care Limited, Suite 4, Ground Floor, Heathrow Boulevard – East Wing, 280 Bath Road, West Drayton, UB7 0DQ, United Kingdom
PLGB 37071/0038
01/05/2021
| Drug | Countries | |
|---|---|---|
| YARGESA | Austria, Estonia, France, Ireland, Italy, Lithuania, Poland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
